ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 683

Referral Strategies for the Early Diagnosis of Axial Spondyloarthritis- a Systematic Review

Abhijeet Danve1 and Atul A. Deodhar2, 1Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: diagnosis, Referrals, spondylarthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Axial Spondyloarthritis (axSpA) is often misdiagnosed or diagnosed late (average delay 8 to 11 years) since low back pain (LBP) is very common in general population and only 5% of those have axSpA. Effective screening and selective referral of high-risk patients (Pt) can help avoid this delay. There are no recommendations for a referral strategy for axSpA in the United States (US). We performed a systematic review to assess the effectiveness of various referral strategies on the final diagnosis of axSpA, and feasibility of their use in US health system.

Methods:

Pubmed and EMBASE search was performed to identify relevant articles using MeSH terms. After screening abstracts and titles of 135 retrieved articles, 9 full length articles were included for initial review.  Three articles were excluded; 2 had different outcome and one was poor quality study. We included a single abstract since it describes the only available study in the US assessing a referral strategy. Final review included 6 full articles and 1 abstract. Data about referral source, referral strategy, Pt characteristics and outcomes were collected. Feasibility was determined by ease of the application of a strategy.

Results:

Most studies used “age at symptom onset <45 years and duration >3 months” as entry criterion (EC) for referral. Pt fulfilling EC only or EC plus combinations of spondyloarthritis (SpA) features (inflammatory back pain (IBP), HLA-B27 (B27), imaging sacroiliitis (iSI), good response to NSAIDS, family history of SpA, uveitis) were referred to rheumatologists. Commonest sources of referral were primary physicians, physical therapists and orthopedists. (See table) Application of simple (EC + 1 of 3 features) and complex strategies (EC + 2 of 5 or 2 of 6 features) produced similar results with 35-45% Pt finally diagnosed as axSpA. Even among studies that used only EC, 33 % to 41% of Pt were diagnosed to have axSpA. Simple strategy of fulfilling EC + 1 of 3 of IBP, B27 and iSI was found to be convenient, feasible and widely acceptable in multicenter studies. Presence of >1 SpA features was associated with higher likelihood of axSpA (24.6%, 44.9%, and 75.5 % for 1, 2 and 3 features respectively).  As a single SpA feature in addition to EC, iSI, B27 and IBP were associated with final diagnosis of axSpA in 50%, 55% and 24% respectively, thus confirming low specificity of IBP.

Conclusion:

Referral strategies are effective tools for screening Pt with chronic back pain for presence of axSpA. Simple strategies work equally well compared to complex strategies. With appropriate application of any strategy, rheumatologist will need to see 2-3 Pt with chronic LBP to identify one Pt with axSpA. We believe that in the US, referring Pt with chronic LBP for >3 months, age of onset <45 years AND one of IBP, B27, iSI to rheumatologist for assessment of possible axSpA would be practical, with an acceptable efficacy.


Disclosure: A. Danve, None; A. A. Deodhar, AbbVie, Amgen, Janssen, Pfizer, Novartis, UCB, 2,Abbvie, Amgen, Janssen, Pfizer, Novartis, UCB, 5.

To cite this abstract in AMA style:

Danve A, Deodhar AA. Referral Strategies for the Early Diagnosis of Axial Spondyloarthritis- a Systematic Review [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/referral-strategies-for-the-early-diagnosis-of-axial-spondyloarthritis-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/referral-strategies-for-the-early-diagnosis-of-axial-spondyloarthritis-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology